Alzheimer’s Disease (AD): Competitive Landscape to 2026

Alzheimer’s disease (AD) is a progressive neurodegenerative disease that is characterized by memory loss, cognitive impairment, and functional decline. The degeneration of neurons starts in the brainstem before progressing to the hippocampus, frontal lobe, amygdala, parietal lobe, and temporal lobe. The cause of AD is unknown, but it appears to be multifactorial, with most research aimed at the Aβ peptides and tau proteins. The irregular clearance and metabolism of these proteins are likely contributors to the presentation of the disease. The risk of developing AD is believed to be determined by a combination of genetic, metabolic, behavioral, and environmental factors.

This report provides an assessment of the pipeline, clinical, and commercial landscape of AD. Overall, GlobalData expects new drug approvals to drive AD market growth over the next decade (2016–2026).

Scope

GlobalData’s Alzheimer’s Disease (AD): Competitive Landscape to 2026 combines data from the Pharma Intelligence Center with in-house analyst expertise to provide a competitive assessment of the disease marketplace.

Components of the slide deck include:

  • Pipeline Assessment—regional breakdown, promising late-stage products, early-stage pipeline by molecule type
  • Clinical Trials Assessment—trial breakdown by phase, leading industry and non-industry sponsors, enrollment analytics
  • Commercial Assessment—leading marketed products, current and future players
  • Competitive Landscape Analysis—key market events (2016–2026)

Reasons to buy

Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.

Develop business strategies by understanding the trends shaping and driving the global AD market.

Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global AD market in the future.

Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.

Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.

Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.

Companies mentioned

Biogen

Eisai Co.

F. Hoffmann-La Roche

Otsuka Pharmaceuticals

Eli Lilly

Ionis Pharmaceuticals

TauRx Therapeutics

Axsome Therapeutics

Accera

Novartis

AZTherapies

AB Science

Grifols

Shanghai Green Valley ...

Biogen

Eisai Co.

F. Hoffmann-La Roche

Otsuka Pharmaceuticals

Eli Lilly

Ionis Pharmaceuticals

TauRx Therapeutics

Axsome Therapeutics

Accera

Novartis

AZTherapies

AB Science

Grifols

Shanghai Green Valley Pharmaceutical

Archer Pharmaceuticals

Changchun Huayang High-Tech

Intra-Cellular Therapies

Avanir Pharmaceuticals

Promis Neurosciences

Pfizer

Johnson & Johnson

AstraZeneca

Janssen

Allergan

Adamas Pharmaceuticals

Lundbeck

Merz Pharma GmbH

Icure Pharmaceutical

Shire

Chase Pharmaceuticals

Table of Contents

Table of Content (PowerPoint Deck)

1 Preface

1.1 Table of Contents

1.2 Abbreviations

1.3 Related Reports

1.4 Upcoming Related Reports

2 ...

Table of Content (PowerPoint Deck)

1 Preface

1.1 Table of Contents

1.2 Abbreviations

1.3 Related Reports

1.4 Upcoming Related Reports

2 Executive Summary

2.1 Key Findings

2.2 Key Events

3 Introduction

3.1 Report Scope

3.2 Disease Overview & Epidemiology

4 Pipeline Assessment

4.1 Pipeline Overview

4.2 Pipeline Breakdown by Region/Country

4.3 Pipeline Breakdown by Molecule Type and Target

4.4 Drug Review Designations

4.5 Products in Clinical Development

5 Clinical Trial Assessment

5.1 Clinical Trials Overview

5.2 Top Sponors of Clinical Trials in AD

5.3 Trial Breakdown by Region

5.4 Therapy Area Perspective

5.5 Enrollment Analytics

6 Commercial Assessment

6.1 Leading Marketed Products

6.2 Current & Future Players

7 Competitive Landscape Analysis (2016–2026)

7.1 Events Classification Overview

7.2 US

7.3 5EU

7.4 Japan

7.5 China

8 Appendix

8.1 Sources

8.2 Methodology

8.3 Key Events Included in the Analysis

8.4 About the Authors

8.5 About GlobalData

8.6 Contact Us

8.7 Disclaimer

    Pricing

Discounts available for multiple report purchases.

reportstore@globaldata.com
+44 (0) 161 359 5813

Saved reports